Pay in 4 interest-free payments of $6.88 Learn more
Ships within 48 hours · Estimated delivery Aug 21 - Aug 26
Absence of clinical safety data No Phase 1 clinical safety trial for BPC-157 has been completed and published
AOD-9604 was subsequently placed in Category 2 of the bulk drug substance nomination list, then later withdrawn from that nomination in April 2026
Immunofluorescence analysis further validated the protein-level alterations of these hub genes and delineated their distinct subcellular localizations in BEAS-2B cells
Here's what to expect
US$ 28.77
US$ 27.93
US$ 20.28
US$ 20.34
US$ 26.68
